Enable Accessibility Enable Accessibility

Takeda Announces New Assignments of Directors

June 29, 2021

OSAKA, Japan, June 29, 2021, --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)

(“Takeda”) today announced new assignment of Directors. The details are as follows;

 

Directors Who are Not Audit and Supervisory Committee Members

 

  1. New assignment of Non-Audit and Supervisory Committee Directors effective June 29, 2021;

Name

Category

Expected Role

Christophe Weber

Internal

Existing

Representative Director,

President & Chief Executive Officer

Masato Iwasaki

Internal

Existing

Representative Director, Japan General Affairs

Andrew Plump

Internal

Existing

Director, President, Research & Development

Constantine Saroukos

Internal

Existing

Director, Chief Financial Officer

Masahiro Sakane

External

Existing

External Director, Chair of the Board Meeting

Olivier Bohuon

External

Existing

External Director

Jean-Luc Butel

External

Existing

External Director

Ian Clark

External

Existing

External Director

Yoshiaki Fujimori

External

Existing

External Director

Steven Gillis

External

Existing

External Director

Shiro Kuniya

External

Existing

External Director

Toshiyuki Shiga

External

Existing

External Director

 

  1. New assignment of Audit and Supervisory Committee Directors effective June 29, 2021;

 

Name

Category

Expected Role

Koji Hatsukawa

External

-

External Director, Chairperson of Audit and Supervisory Committee

Emiko Higashi

External

-

External Director, Audit and Supervisory Committee Member

Masami Iijima

External

New

External Director, Audit and Supervisory Committee Member

Michel Orsinger

External

-

External Director, Audit and Supervisory Committee Member

 

Koji Hatsukawa, Emiko Higashi, and Michel Orsinger are within their 2-year tenure of Audit and Supervisory Committee Director, and were not subjects for reelection this year.

 

  1. New assignment of Compensation committee and Nomination committee effective June 29, 2021;

 

Compensation committee : Emiko Higashi (Chair), Olivier Bohuon, Ian Clark, Yoshiaki Fujimori
Nomination committee : Masahiro Sakane (Chair), Jean-Luc Butel, Steven Gillis,
Toshiyuki Shiga, Michel Orsinger, Christophe Weber (Observer)

 

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven
biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

 

Media Contacts:
Japanese Media
Ryoko Matsumoto
ryoko.matsumoto@takeda.com
+81 (0) 3-3278-3414

 

Media Outside Japan
Christina Beckerman
christina.beckerman@takeda.com
+1 (908) 581-4133